Enhancing topical ruxolitinib delivery via emulgel for vitiligo: formulation development, in vitro release, skin permeation, and mechanistic effects on melanogenesis
Topical ruxolitinib delivery significantly improved melanogenesis when using an emulgel formulation, leading to better outcomes in vitiligo treatment.
Release studies indicated a controlled in vitro release profile over a 24-hour period, establishing effective drug availability.
Skin permeation tests demonstrated enhanced absorption of ruxolitinib through emulgel compared to conventional formulations, reaching deeper layers of skin.
These findings highlight the potential of emulgel formulations for optimizing drug delivery in dermatological therapies, warranting further clinical validation.